Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

9

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Muscarinic acetylcholine receptor M1

8

Muscarinic acetylcholine receptor M2

8

Muscarinic acetylcholine receptor M3

8

Muscarinic acetylcholine receptor M4

8

Muscarinic acetylcholine receptor M5

8

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

9

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1961

8

2011

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Chronic obstructive pulmonary disease

9

Peptic ulcer

8

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

8

Secondary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

8

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Sosei

8

Altana

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

9

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

9

FDA UNII

9

PUBCHEM

9

EPA CompTox

5

SMS_ID

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

3

ALIMENTARY TRACT AND METABOLISM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

3

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ADRENERGICS, INHALANTS

2

OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS

2

ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS

1

DRUGS FOR FUNCTIONAL BOWEL DISORDERS

1

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Adrenergics in combination with anticholinergics

2

Anticholinergics

2

Synthetic anticholinergics, quaternary ammonium compounds

2

Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids

1

Other systemic drugs for obstructive airway diseases

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 9 of 9 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Roflumilast

0P6C6ZOP5U

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2011

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Phosphodiesterase 4

Conditions:

Chronic obstructive pulmonary disease

Roflumilast is a specific phosphodiesterase type (4PDE4) inhibitor indicated for use as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

GLYCOPYRRONIUM

A14FB57V1D

Export Data
Search for Structure

Status:

US Approved Rx (2009)

First approved in 1961

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M5

Conditions:

Chronic obstructive pulmonary disease

Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. Glycopyrrolate is a muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with s...

ome anesthetics. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Like other anticholinergic (antimuscarinic) agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily. Glycopyrrolate is marketed under the brand names Robinul, Robinul Forte, Cuvposa. In October 2015, glycopyrrolate was approved by the FDA for use as a standalone treatment for Chronic obstructive pulmonary disease (COPD), as Seebri Neohaler.

GLYCOPYRRONIUM, (2R,3'S)-

HTB34557V4

Export Data
Search for Structure

Status:

US Approved Rx (2009)

First approved in 1961

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M5

Conditions:

Chronic obstructive pulmonary disease

Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. Glycopyrrolate is a muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with s...

ome anesthetics. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Like other anticholinergic (antimuscarinic) agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily. Glycopyrrolate is marketed under the brand names Robinul, Robinul Forte, Cuvposa. In October 2015, glycopyrrolate was approved by the FDA for use as a standalone treatment for Chronic obstructive pulmonary disease (COPD), as Seebri Neohaler.

GLYCOPYRRONIUM TOSYLATE ANHYDROUS, (2R,3'S)-

2TGG71ISBK

Export Data
Search for Structure

Status:

US Approved Rx (2009)

First approved in 1961

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M5

Conditions:

Chronic obstructive pulmonary disease

Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. Glycopyrrolate is a muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with s...

ome anesthetics. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Like other anticholinergic (antimuscarinic) agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily. Glycopyrrolate is marketed under the brand names Robinul, Robinul Forte, Cuvposa. In October 2015, glycopyrrolate was approved by the FDA for use as a standalone treatment for Chronic obstructive pulmonary disease (COPD), as Seebri Neohaler.

GLYCOPYRRONIUM TOSYLATE ANHYDROUS

43UR76B63P

Export Data
Search for Structure

Status:

US Approved Rx (2009)

First approved in 1961

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M5

Conditions:

Chronic obstructive pulmonary disease

Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. Glycopyrrolate is a muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with s...

ome anesthetics. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Like other anticholinergic (antimuscarinic) agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily. Glycopyrrolate is marketed under the brand names Robinul, Robinul Forte, Cuvposa. In October 2015, glycopyrrolate was approved by the FDA for use as a standalone treatment for Chronic obstructive pulmonary disease (COPD), as Seebri Neohaler.

GLYCOPYRROLATE, (2R,3'S)-

68EL47CXSP

Export Data
Search for Structure

Status:

US Approved Rx (2009)

First approved in 1961

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M5

Conditions:

Chronic obstructive pulmonary disease

Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. Glycopyrrolate is a muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with s...

ome anesthetics. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Like other anticholinergic (antimuscarinic) agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily. Glycopyrrolate is marketed under the brand names Robinul, Robinul Forte, Cuvposa. In October 2015, glycopyrrolate was approved by the FDA for use as a standalone treatment for Chronic obstructive pulmonary disease (COPD), as Seebri Neohaler.

GLYCOPYRRONIUM TOSYLATE, (2R,3'S)-

5RA98MRV4Z

Export Data
Search for Structure

Status:

US Approved Rx (2009)

First approved in 1961

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M5

Conditions:

Chronic obstructive pulmonary disease

Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. Glycopyrrolate is a muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with s...

ome anesthetics. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Like other anticholinergic (antimuscarinic) agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily. Glycopyrrolate is marketed under the brand names Robinul, Robinul Forte, Cuvposa. In October 2015, glycopyrrolate was approved by the FDA for use as a standalone treatment for Chronic obstructive pulmonary disease (COPD), as Seebri Neohaler.

GLYCOPYRRONIUM TOSYLATE

1PVF6JLU7B

Export Data
Search for Structure

Status:

US Approved Rx (2009)

First approved in 1961

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M5

Conditions:

Chronic obstructive pulmonary disease

Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. Glycopyrrolate is a muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with s...

ome anesthetics. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Like other anticholinergic (antimuscarinic) agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily. Glycopyrrolate is marketed under the brand names Robinul, Robinul Forte, Cuvposa. In October 2015, glycopyrrolate was approved by the FDA for use as a standalone treatment for Chronic obstructive pulmonary disease (COPD), as Seebri Neohaler.

GLYCOPYRROLATE

V92SO9WP2I

Export Data
Search for Structure

Status:

US Approved Rx (2009)

First approved in 1961

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M5

Conditions:

Chronic obstructive pulmonary disease

Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. Glycopyrrolate is a muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with s...

ome anesthetics. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Like other anticholinergic (antimuscarinic) agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily. Glycopyrrolate is marketed under the brand names Robinul, Robinul Forte, Cuvposa. In October 2015, glycopyrrolate was approved by the FDA for use as a standalone treatment for Chronic obstructive pulmonary disease (COPD), as Seebri Neohaler.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1